VYDURA Trademark

Trademark Overview


On Wednesday, January 16, 2019, a trademark application was filed for VYDURA with the United States Patent and Trademark Office. The USPTO has given the VYDURA trademark a serial number of 88264650. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 15, 2022. This trademark is owned by Biohaven Pharmaceutical Holding CompanyLimited. The VYDURA trademark is filed in the Pharmaceutical Products category with the following description:

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclero...
vydura

General Information


Serial Number88264650
Word MarkVYDURA
Filing DateWednesday, January 16, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 15, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 14, 2019

Trademark Statements


Goods and ServicesMedicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine-adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 8, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBIOHAVEN PHARMACEUTICAL IRELAND DAC
Party Type21 - New Owner After Publication
Legal Entity Type99 - Other
AddressDUBLIN 4 D04 TR29
IE

Party NameBiohaven Pharmaceutical Holding CompanyLimited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressNew Haven, CT 06510

Party NameBiohaven Pharmaceutical Holding CompanyLimited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressNew Haven, CT 06510

Trademark Events


Event DateEvent Description
Monday, August 15, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 15, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 13, 2022AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Saturday, January 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 7, 2022SOU EXTENSION 5 GRANTED
Tuesday, January 4, 2022SOU EXTENSION 5 FILED
Tuesday, January 4, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 2, 2021SOU EXTENSION 4 GRANTED
Friday, July 2, 2021SOU EXTENSION 4 FILED
Friday, July 2, 2021SOU TEAS EXTENSION RECEIVED
Thursday, January 7, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 5, 2021SOU EXTENSION 3 GRANTED
Tuesday, January 5, 2021SOU EXTENSION 3 FILED
Tuesday, January 5, 2021SOU TEAS EXTENSION RECEIVED
Thursday, July 2, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 1, 2020SOU EXTENSION 2 GRANTED
Wednesday, June 17, 2020SOU EXTENSION 2 FILED
Wednesday, July 1, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 17, 2020SOU TEAS EXTENSION RECEIVED
Saturday, December 21, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 19, 2019SOU EXTENSION 1 GRANTED
Thursday, December 19, 2019SOU EXTENSION 1 FILED
Thursday, December 19, 2019SOU TEAS EXTENSION RECEIVED
Wednesday, October 23, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, October 23, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 9, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 14, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 14, 2019PUBLISHED FOR OPPOSITION
Wednesday, April 24, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 29, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 28, 2019ASSIGNED TO EXAMINER
Friday, February 8, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, January 19, 2019NEW APPLICATION ENTERED